158 related articles for article (PubMed ID: 17300168)
1. Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities.
Cuisiat S; Bourdiol N; Lacharme V; Newman-Tancredi A; Colpaert F; Vacher B
J Med Chem; 2007 Feb; 50(4):865-76. PubMed ID: 17300168
[TBL] [Abstract][Full Text] [Related]
2. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
Bruins Slot LA; Lestienne F; Grevoz-Barret C; Newman-Tancredi A; Cussac D
Eur J Pharmacol; 2009 Oct; 620(1-3):27-35. PubMed ID: 19695244
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
Heusler P; Newman-Tancredi A; Loock T; Cussac D
Eur J Pharmacol; 2008 Feb; 581(1-2):37-46. PubMed ID: 18190908
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R
Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418
[TBL] [Abstract][Full Text] [Related]
5. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
Assié MB; Ravailhe V; Faucillon V; Newman-Tancredi A
J Pharmacol Exp Ther; 2005 Oct; 315(1):265-72. PubMed ID: 15987834
[TBL] [Abstract][Full Text] [Related]
6. F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.
Newman-Tancredi A; Assié MB; Martel JC; Cosi C; Slot LB; Palmier C; Rauly-Lestienne I; Colpaert F; Vacher B; Cussac D
Br J Pharmacol; 2007 May; 151(2):237-52. PubMed ID: 17375087
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship studies of CNS agents. XII. 1-[4-(4-aryl-1-piperazinyl)butyl]-3,4-dihydro-2(1H)-quinolinones: new 5-HT1A, 5-HT2 and D2 ligands with a potential antipsychotic activity.
Mokrosz JL; Chojnacka-Wójcik E; Dereń-Wesołek A; Kłodzińska A; Maćkowiak M; Bielecka Z; Paluchowska MH
Drug Des Discov; 1994 Apr; 11(3):197-203. PubMed ID: 7548635
[TBL] [Abstract][Full Text] [Related]
8. Novel 4-alkyl-1-arylpiperazines and 1,2,3,4-tetrahydroisoquinolines containing diphenylmethylamino or diphenylmethoxy fragment with differentiated 5-HT1A/5-HT2A/D2 receptor activity.
Paluchowska MH; Mokrosz MJ; Charakchieva-Minol S; Duszyńska B; Kozioł A; Wesołowska A; Stachowicz K; Chojnacka-Wójcik E
Pol J Pharmacol; 2003; 55(4):543-52. PubMed ID: 14581712
[TBL] [Abstract][Full Text] [Related]
9. High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity.
Maurel JL; Autin JM; Funes P; Newman-Tancredi A; Colpaert F; Vacher B
J Med Chem; 2007 Oct; 50(20):5024-33. PubMed ID: 17803293
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of a series of 6-substituted-2-pyridinylmethylamine derivatives as novel, high-affinity, selective agonists at 5-HT1A receptors.
Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C
J Med Chem; 1998 Dec; 41(25):5070-83. PubMed ID: 9836623
[TBL] [Abstract][Full Text] [Related]
11. Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice.
Bruins Slot LA; Bardin L; Auclair AL; Depoortere R; Newman-Tancredi A
Behav Pharmacol; 2008 Mar; 19(2):145-52. PubMed ID: 18332679
[TBL] [Abstract][Full Text] [Related]
12. 1,4-Benzoxazin-3(4H)-one derivatives and related compounds as 5-HT1A and 5-HT2A receptor ligands; the effect of the terminal amide fragment on the 5-HT1A/5-HT2A affinity and functional activity.
Mokrosz MJ; Kowalski P; Kowalska T; Majka Z; Duszyńska B; Charakchieva-Minol S; Szaro A; Tatarczyńska E; Kłodzińska A; Chojnacka-Wójcik E
Pol J Pharmacol; 1998; 50(4-5):333-40. PubMed ID: 10091718
[TBL] [Abstract][Full Text] [Related]
13. SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats.
Boulay D; Depoortère R; Louis C; Perrault G; Griebel G; Soubrié P
Neuropharmacology; 2004 Jun; 46(8):1121-9. PubMed ID: 15111019
[TBL] [Abstract][Full Text] [Related]
14. Stereoselectivity of 8-OH-DPAT toward the serotonin 5-HT1A receptor: biochemical and molecular modeling study.
Dabrowska J; Brylinski M
Biochem Pharmacol; 2006 Aug; 72(4):498-511. PubMed ID: 16796994
[TBL] [Abstract][Full Text] [Related]
15. Serotonin 5-HT2 receptor, dopamine D2 receptor, and alpha 1 adrenoceptor antagonists. Conformationally flexible analogues of the atypical antipsychotic sertindole.
Andersen K; Liljefors T; Hyttel J; Perregaard J
J Med Chem; 1996 Sep; 39(19):3723-38. PubMed ID: 8809161
[TBL] [Abstract][Full Text] [Related]
16. Serotonin(1A) receptor agonism in the expression of behavioral dopaminergic supersensitivity in subchronic haloperidol treated rats.
Batool F; Haleem DJ
Pak J Pharm Sci; 2008 Oct; 21(4):411-20. PubMed ID: 18930864
[TBL] [Abstract][Full Text] [Related]
17. F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release.
Assié MB; Mnie-Filali O; Ravailhe V; Benas C; Marien M; Bétry C; Zimmer L; Haddjeri N; Newman-Tancredi A
Eur J Pharmacol; 2009 Apr; 607(1-3):74-83. PubMed ID: 19326477
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.
Butini S; Gemma S; Campiani G; Franceschini S; Trotta F; Borriello M; Ceres N; Ros S; Coccone SS; Bernetti M; De Angelis M; Brindisi M; Nacci V; Fiorini I; Novellino E; Cagnotto A; Mennini T; Sandager-Nielsen K; Andreasen JT; Scheel-Kruger J; Mikkelsen JD; Fattorusso C
J Med Chem; 2009 Jan; 52(1):151-69. PubMed ID: 19072656
[TBL] [Abstract][Full Text] [Related]
19. Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds.
Depoortère R; Barret-Grévoz C; Bardin L; Newman-Tancredi A
Eur J Pharmacol; 2008 Nov; 597(1-3):34-8. PubMed ID: 18773888
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, binding affinity, and molecular docking analysis of new benzofuranone derivatives as potential antipsychotics.
Aranda R; Villalba K; Raviña E; Masaguer CF; Brea J; Areias F; Domínguez E; Selent J; López L; Sanz F; Pastor M; Loza MI
J Med Chem; 2008 Oct; 51(19):6085-94. PubMed ID: 18783204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
